Mirabegron Dosing and Management for Overactive Bladder

Patient Selection and Dosing

For elderly patients, particularly those ≥80 years with multiple comorbidities, the American Urological Association recommends starting with a 25 mg dose, which produces statistically significant improvements in voiding symptoms and quality of life with an acceptable adverse event rate of 24.62% 1
The standard dosing regimen for mirabegron is 25 mg orally once daily, which may be increased to 50 mg once daily after 4-8 weeks if inadequate symptom control is observed, and this approach is supported by clinical guidelines from the European Association of Urology 1

The American Heart Association recommends monitoring blood pressure periodically, especially during initial treatment with mirabegron, as it can cause dose-dependent blood pressure increases 1
Mirabegron is contraindicated in patients with severe uncontrolled hypertension, as stated by the American College of Cardiology 1
The International Continence Society recommends regular re-evaluation of post-void residual volume, particularly in men with lower urinary tract symptoms 2

For patients with inadequate response to mirabegron monotherapy after 6 months, the European Association of Urology recommends adding solifenacin 5 mg once daily to mirabegron (either 25 mg or 50 mg), as combination therapy shows superior efficacy with effect sizes exceeding monotherapy 1, 2
The American Urological Association notes that combination therapy is associated with a slightly increased risk of adverse events, including dry mouth, constipation, and urinary retention, compared to monotherapy 3
The SYNERGY trials demonstrated that combination therapy was statistically superior to either monotherapy for decreasing incontinence episodes and micturitions over 12 months, as reported by the National Institute for Health and Care Excellence 3

The American Urological Association recommends starting mirabegron at 25 mg once daily when switching from Gemtesa (vibegron) 75mg, as there is no established dose equivalency between these medications, and no literature supports direct conversion ratios 4, 5

The European Association of Urology suggests that a conservative starting approach with mirabegron 25 mg once daily provides significant efficacy improvements over placebo while minimizing cardiovascular risks, although the exact evidence is not provided in this context, dose equivalency between vibegron and mirabegron is not established 4, 5

The International Consultation on Incontinence recommends considering maintaining the 25 mg dose longer (beyond 8 weeks) before escalation in frail elderly patients, as the 25 mg starting dose is particularly appropriate for older patients with multiple comorbidities, demonstrating both safety and therapeutic efficacy, however the exact evidence is not provided in this context, and dose adjustments may be necessary for patients with renal or hepatic impairment 4, 5

The American Urological Association advises against assuming dose equivalency between vibegron 75 mg and mirabegron 50 mg, as these are different molecules requiring independent dose titration 4, 5